Andy Kinley, Ph.D. is Vice President of Operational Strategy at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Dr. Kinley specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells).

Rebecca Donahue is the Associate Director of Medical Affairs at Merck Sharp & Dohme LLC, United States. With over a decade of progressive leadership experience, including six years in the pharmaceutical industry, she is passionate about amplifying the voices of patients and care partners. She is dedicated to fostering meaningful connections, ensuring that the perspectives of patients and caregivers are captured and integrated into the organization throughout the product life cycle.

Rebecca supports various patient engagement initiatives, including Patient Advisory Panels and Nurse Network Activities. She collaborates and supports both internal stakeholders and external partners to oversee the end-to-end process involved in these engagement activities. Rebecca is deeply committed to ensuring that every initiative keeps the patient at the center and that all deliverables are both understandable and health literate.

Dr. Zilberberg studied chemical engineering at Universidad Simón Bolívar in Venezuela and then joined the graduate program in bioengineering at Penn State where she obtained her M.S. and Ph.D. She conducted further training in the fields of vascular biology and cancer immunotherapy at UPenn and Thomas Jefferson University and held an Associate Member position at Center for Discovery and Innovation, part of Hackensack Meridian Health. She holds two patents for the development of ex vivo culture platforms to study the bone and bone marrow niches, has authored numerous publications, and has been the recipient of multiple NIH-funded grants. In 2020, she joined Imvax to lead the research and translational efforts for the company’s Goldspire® immunotherapy platform. Dr. Zilberberg serves as an ad-hoc reviewer for NCI’s Innovative Molecular Analysis Technologies (IMAT) program and is a member of the Scientific Advisory Board of FIG Therapeutics.

Peter Luo, PhD is the Co-Founder and has served as the Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July 1998 to August 2000. In September 2000, Dr Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006, Dr Luo led the acquisition of Abmaxis Inc. by Merck & Co. (NYSE: MRK), after which Dr Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr Luo received his bachelor’s degree in applied chemistry in technical physics from Peking University in 1986, master’s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and PhD degree in chemistry from The University of Chicago in 1995. Dr Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.

Dr Salvatore “Salvo” Alesci is the Chief Scientific Officer of Invea Therapeutics, Inc. In his role, Dr. Alesci is responsible to lead a multidisciplinary team of drug discovery, data science, translational, clinical, commercial and IP experts to initiate and progress programs from target validation to early clinical development, with the primary goal of building an innovative AI-powered derisked pipeline of drug candidates for immune-mediated inflammatory diseases (IMIDs).

Dr Alesci received his MD (cum laude) and a PhD in Experimental Endocrine and Metabolic Sciences from University of Messina, School of Medicine (Italy), where he also did his clinical training in Endocrinology. He also completed a Research Fellowship in Rheumatology, Immunology and Allergy at Georgetown University. After his post- graduate training, Dr Alesci spent almost a decade conducting cutting-edge basic and translational research on the interplay between the neuroendocrine and immune systems at the National Institutes of Health (NIH). His last appointment was Staff Scientist at the Clinical Neuroendocrinology Branch, National Institute of Mental Health.

From 2006 to 2011, Dr Alesci served in a number of Translational Medicine leadership roles at Wyeth, Pfizer and Merck covering multiple therapy areas and large and diverse drug portfolios. In 2011, Dr Alesci joined PhRMA as Vice President, Scientific & Regulatory Affairs to lead the association’s science advocacy and engagement efforts, serving as chief scientific and medical expert for input on biomedical policy issues. After his departure from PhRMA in 2015, Dr Alesci joined Takeda, where his last appointment was Head, R&D Global Patient and Scientific Affairs.

More recently, Dr Alesci has served as Chief Scientist and Strategy Officer and Chair of the Scientific Advisory Council at Beyond Celiac, the leading research-driven patient advocacy organization focused on accelerating discovery and development of treatments for Celiac disease, a disease that among others affects his daughter and son.

David A Braun, MD, PhD is the Louis Goodman and Alfred Gilman Yale Scholar and an Assistant Professor of Medicine, Pathology, and Urology at the Yale School of Medicine. He is a medical oncologist specializing in the care of patients with kidney cancer, and the Principal Investigator of an NIH- and DOD-funded caner immunology at the Center of Molecular and Cellular Oncology within the Yale Cancer Center. His laboratory uses computational and experimental immunology approaches to understand the immunobiology of renal cell carcinoma. For these efforts, he was awarded an R37 MERIT Award from the NCI, given the Trailblazer Award and the Christopher Wood Rising Star Award from the Kidney Cancer Association and was elected to membership in the American Society for Clinical Investigation (ASCI).

Evan Zisholtz, JD is Vice President of Global Business Development at Immunai, and oversees both BD and M&A. Prior to Immunai, Evan supported M&A and Corporate Strategy at Lonza. Mr Zisholtz began his career as an attorney in private practice in New York and holds a JD from New York University School of Law.

Dr Greg Licholai is Chief Medical and Innovation Officer at ICON plc, a global healthcare intelligence and clinical research organization. He is on the faculty at Yale School of Management and is Co-Director of the Center for Digital Health. Previously, he was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. He was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates. He was co-founder of Immunome Therapeutics.

Greg has degrees from Harvard Business School, Yale School of Medicine, Columbia University and Boston College. He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. He serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). He writes about innovation in healthcare for Forbes.

Ben Glass is Vice President of Product and Translational Research at PathAI. Mr Glass leads the product organizations at PathAI, managing teams of product managers and scientists in the development of an AI based portfolio of products as well as the software platform AISight, the leading digital pathology platform. Additionally, Mr Glass oversees the translational research which focuses on developing and deploying artificial intelligence algorithms ranging from biomarker discovery, clinical trial enrollment and endpoint assessment and companion diagnostics with PathAI’s biopharma and strategic partners. Mr Glass has co-authored over 70 publications and inventions. Prior to joining PathAI, Mr Glass was a member of the Beck Lab at Harvard Medical School/BIDMC, focusing on applying computational methods for pathology and genomics research. Mr Glass completed his MS in Bioinformatics focusing on computational methods at Northeastern University and has a BS in Biology from the University of Massachusetts Amherst.

Campbell Hutton, is Senior Vice President, Global Advocacy at Breakthrough T1D, a non-profit organization whose mission is to accelerate life-changing breakthroughs to cure, prevent and treat type 1 diabetes (T1D) and its complications. In her role she oversees the regulatory affairs and health policy teams within the Advocacy Department as well as the advocacy work in the European Union (EU). Ms. Hutton joined Breakthrough T1D in 2009 as Director, Regulatory Affairs – Medical Devices and since that time has focused on shaping policies that will accelerate the research, development, approval and availability of innovative T1D therapies. Prior to joining JDRF, Ms. Hutton was Vice President, Strategic Consulting Group at Becker & Associates Consulting, a boutique scientific consulting firm in Washington, D.C. Ms. Hutton holds a bachelor’s degree in biology from Washington and Lee University and a master’s degree in public health from the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill.

Peter Linde, MD, FASN, is a clinical development leader with 19 years of experience in leading global teams for Phase I and II clinical trials at companies like Morphic Therapeutics, Acceleron, and Abbvie. In his role at Thermo Fisher Scientific, he supports biotech customers as vice president, global medical officer for the PPD clinical research business. His work has resulted in four global regulatory approvals and company acquisitions by Merck and Lilly. He holds two U.S. patents in stem cell biology and extracorporeal organ devices, with another pending for Sotatercept in Pulmonary Arterial Hypertension. Peter completed nephrology and transplant fellowships at Massachusetts General Hospital/Harvard and served as a Clinical Assistant Professor of Medicine at UCSF prior to his career in the pharmaceutical industry.

TBA